A Multicenter, Double-blind, Placebo- and Active-Controlled Parallel-Group Evaluation of the Safety and Efficacy of Vilazodone in Pediatric Patients With Major Depressive Disorder
Phase of Trial: Phase III
Latest Information Update: 13 Feb 2017
At a glance
- Drugs Vilazodone (Primary) ; Fluoxetine
- Indications Major depressive disorder
- Focus Registrational; Therapeutic Use
- Sponsors Allergan; Forest Laboratories
- 09 Jun 2016 Planned End Date changed from 1 May 2017 to 1 Jun 2017.
- 04 Mar 2015 New trial record
- 03 Mar 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.